TG Therapeutics Announces Data from the ULTIMATE I and II Ph

TG Therapeutics Announces Data from the ULTIMATE I and II Phase 3 Trials of BRIUMVI in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting

NEW YORK - TG Therapeutics, Inc. , today announced the details of an upcoming oral presentation, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI in patients with... | June 1, 2023

Related Keywords

Colorado , United States , Lawrence Steinman , Enrique Alvarez , Consortium Of Multiple Sclerosis Centers , International Journal , Biopharmaceutical Company , Stanford University , Neurological Sciences , Tg Therapeutics Inc , University Of Colorado , Nasdaq , Exchange Commission , Multiple Sclerosis Centers , Ublituximab Is Associated , Significant Improvement , Disease Modifying Therapies , Expanded Disability Status Scale , Private Securities Litigation Reform Act , Annual Report , News Publishing , Tg Therapeutics , Nc Stock Exchange , News , Information , Press Release , Few , Work , G , Oday , Nnounced , The , Details , F , N , Pcoming , Mural , Ighlighting , Data , Rom , Ultimate , , Hi , Hase , Trials , Valuating , Riumvi , Atients Tgtx Us88322q1085 ,